(Q48210503)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author

Francisco Pérez-Miralles

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Mar Tintoré

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Angela Vidal-Jordana

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Jaume Sastre Garriga

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Carmen Tur

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Alejandro Horga

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Jordi Rio

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

María Jesús Arévalo

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Xavier Montalban

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Cristina Auger

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Carlos Nos

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Mari C Edo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Joaquín Castilló

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Alex Rovira

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

14 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

1175-1181

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

The measurement and clinical relevance of brain atrophy in multiple sclerosis

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Measuring brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Three years of experience: the Italian registry and safety data update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Normalized accurate measurement of longitudinal brain change.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Voxel-based morphometry–the methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Impact of inflammation on brain volume in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Gray and white matter volume changes in early RRMS: a 2-year longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512473190

21 January 2018

Identifiers

DOI

10.1177/1352458512473190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23319072%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference